TY  - CONF

T1  - Abstract CT330: Adjusting for confounding effects of treatment crossover in a randomized phase 2 study of dabrafenib plus trametinib in <i>BRAF</i> V600+ metastatic melanoma

JO  - Cancer Research

UR  - https://doi.org/10.1158/1538-7445.am2014-ct330

PY  - 2014/10/01

AU  - Latimer N

AU  - Amonkar M

AU  - Stapelkamp C

AU  - Sun P

ED  - 

DO  - DOI: 10.1158/1538-7445.am2014-ct330

PB  - American Association for Cancer Research (AACR)

VL  - 74

IS  - 19_Supplement

SP  - CT330

EP  - CT330

Y2  - 2025/11/04

ER  -